Advances in sarcoma genomics and new therapeutic targets Journal Article
| Authors: | Taylor, B. S.; Barretina, J.; Maki, R. G.; Antonescu, C. R.; Singer, S.; Ladanyi, M. |
| Article Title: | Advances in sarcoma genomics and new therapeutic targets |
| Abstract: | Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma. © 2011 Macmillan Publishers Limited. All rights reserved. |
| Keywords: | osteosarcoma; signal transduction; treatment response; primary tumor; unclassified drug; mutation; review; sorafenib; bevacizumab; erlotinib; sunitinib; nonhuman; antineoplastic agents; drug targeting; cancer adjuvant therapy; cancer patient; antineoplastic agent; animals; mice; gastrointestinal stromal tumor; imatinib; unindexed drug; lung non small cell cancer; dasatinib; chronic myeloid leukemia; angiosarcoma; cancer resistance; cixutumumab; panitumumab; protein tyrosine kinase inhibitor; ewing sarcoma; sarcoma; cancer genetics; transcription regulation; angiomyolipoma; genomic instability; gefitinib; gene fusion; cediranib; pazopanib; genomics; nijmegen breakage syndrome; mesenchymal stem cell; genome; trabectedin; hemangiopericytoma; leiomyosarcoma; rhabdomyosarcoma; solitary fibrous tumor; synovial sarcoma; trastuzumab; mammalian target of rapamycin inhibitor; tumor gene; malignant peripheral nerve sheath tumor; nerve sheath tumor; chondrosarcoma; chordoma; rapamycin; phosphotransferase inhibitor; liposarcoma; clear cell sarcoma; nuclear reprogramming; desmoid tumor; alveolar soft part sarcoma; desmoplastic small round cell tumor; myxosarcoma; n (2,3 dihydroxypropoxy) 3,4 difluoro 2 (2 fluoro 4 iodoanilino)benzamide; endometrial stromal tumor; hemangioendothelioma; dermatofibrosarcoma protuberans; copy number variation; plasma cell granuloma; fibromatosis; giant cell tumor; denosumab; enchondroma; lymphangioleiomyomatosis; chir 265; receptor antibody; ridaforolimus; vismodegib; crizotinib; olaratumab; scatter factor receptor inhibitor; somatomedin c receptor antibody; vemurafenib; angiomatoid fibrous histiocytoma; chondroma; congenital fibrosarcoma; dedifferentiated liposarcoma; fibromyxoid sarcoma; mesenchyme chondrosarcoma; nucleotide binding site; pigmented villonodular synovitis; rothmund thomson syndrome; werner syndrome |
| Journal Title: | Nature Reviews Cancer |
| Volume: | 11 |
| Issue: | 8 |
| ISSN: | 1474-175X |
| Publisher: | Nature Publishing Group |
| Date Published: | 2011-07-14 |
| Start Page: | 541 |
| End Page: | 557 |
| Language: | English |
| DOI: | 10.1038/nrc3087 |
| PUBMED: | 21753790 |
| PROVIDER: | scopus |
| PMCID: | PMC3361898 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 October 2011" - "CODEN: NRCAC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work